Finanzen von Vaxcyte Inc (PCVX)PCVXVaxcyte Inc

Evaluating the bottom line, Vaxcyte, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -36.51%, provide a clear picture of how effectively PCVX converts its operational activities into shareholder value.

In the context of the broader market, PCVX competes directly with industry leaders such as IMVT and TWST. With a market capitalization of $8.64B, it holds a significant position in the sector. When comparing efficiency, PCVX's gross margin of N/A stands against IMVT's N/A and TWST's 52.76%. Such benchmarking helps identify whether Vaxcyte, Inc. is trading at a premium or discount relative to its financial performance.

Vaxcyte's financial performance shows a troubling trend with increasing net losses, reaching -$320.6 million in Q1 2026 and -$284.3 million in Q2 2026. The company's EPS has consistently been negative, with the latest reported EPS at -$1.97, which is worse than expected.